Botanix Pharmaceuticals (BOT) Q4 2025 TU earnings summary

Executive summary

• Q4 FY2025 marked the first full quarter since the commercial launch of Sofdra, targeting primary axillary hyperhidrosis, a large and underserved dermatology market in the US.

• Sofdra net revenue surged from $0.7M in Q3 to $4.3M in Q4, with gross sales reaching $20.4M and prescriptions shipped up 324% quarter-over-quarter.

• Unique prescribers increased 115% to 2,316, and new patient arrivals more than doubled to 7,053 in Q4.

• The company is well-funded, with $64.9M in cash and over $27M in inventory at year-end, and undrawn debt of $15.3M.

• The sales team rapidly generated significant demand, with high refill rates exceeding industry standards.

Financial highlights

• Q4 gross sales rose to $20.4M from $4.8M in Q3; net revenue increased to $4.3M from $0.7M.

• Total prescriptions shipped in Q4 increased 324% to 13,647, with unique prescribers up 115% to 2,316.

• Operating cash outflow for Q4 was negative $28.4M, mainly due to $11.2M in inventory purchases; outflows expected to decline next quarter.

• Financing cash inflow for the quarter was $65.6M, including a $40M institutional placement and a $30.7M debt facility drawdown.

• Cash and cash equivalents at quarter-end were $64.9M, up from $28.1M in the previous quarter.

Outlook and guidance

• Cash outflow is expected to decrease and stabilize as net sales grow, with no further drug substance or significant inventory purchases planned for H1 FY2026.

• The company aims to reach a gross to net yield of 30%-40% as seen in leading US dermatology firms, with current GTN at 23%.

• Expansion of the sales force is underway, with 17 new reps to be trained in Q1 FY2026 and further growth planned for Q2 FY2026.

• Management expects to reach profitability with current cash reserves and continued sales momentum.

• Revenue expected to rise quarter-on-quarter as Sofdra gains market traction.